Showing results (641-650 of 3,042) with videos related to
Sort By:
Pageof 305
Autoimmunity Reviews|March 23, 2024
Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseasesMirre De Bondt, Janne Renders, Sofie Struyf, et al.Autoimmunity Reviews|July 23, 2023
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remissionRoberto Giacomelli, Roberto Caporali, Francesco Ciccia, et al.Autoimmunity Reviews|March 28, 2026
Prevalence and clinical significance of anti-NOR90 antibodies in systemic sclerosis: Results from a multicentre cohort and systematic literature reviewJavier Narváez, Miguel Ángel González-Gay, Francisco Morandeira, et al.Autoimmunity Reviews|October 16, 2023
Should we use nintedanib as early therapy in patients with SSc-ILD?Elisabetta Zanatta, Beatrice Moccaldi, Gabriella Szucs, et al.Autoimmunity Reviews|September 6, 2023
Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototypeA Razzaque Ahmed, Mikole Kalesinskas, Sarah Kooper-JohnsonAutoimmunity Reviews|September 7, 2023
SpA plus IBD or IBD plus SpA: Does commutative property apply?Francesco Carubbi, Alessia Alunno, Angelo Viscido, et al.Autoimmunity Reviews|August 31, 2023
To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debateMaurizio Cutolo, Yehuda Shoenfeld, Dimitrios P Bogdanos, et al.Autoimmunity Reviews|August 31, 2023
Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis?Dario Roccatello, Roberto Padoan, Savino Sciascia, et al.Autoimmunity Reviews|September 10, 2023
Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?Corrado Campochiaro, Yannick Allanore, Yolanda Braun-Moscovici, et al.Autoimmunity Reviews|March 31, 2026
The role of myeloid-derived suppressor cells in Sjögren's diseaseLiang Jin, Chenxu Yang, Jianping Gan, et al.Pageof 305